Patents by Inventor Edward A. Glazer

Edward A. Glazer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7439058
    Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: October 21, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mark Selby, Edward Glazer, Michael Houghton
  • Patent number: 7429385
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: September 30, 2008
    Assignee: Novartis Vaccines & Diagnostics
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Publication number: 20050044033
    Abstract: A like-kind exchange method wherein an accommodator acquires a property on behalf of an exchanger and establishes itself as the tax owner of the acquired property by becoming liable to pay on at least a portion of a debt on the acquired property. The accommodator then leases the acquired property to the exchanger with an option to buy. During the term of the lease, the exchanger is free to perform any desired development work on the acquired property. With this procedure, the acquired property is available as a replacement property in a like-kind exchange by the exchanger for longer than the 180 day time limitation imposed by Revenue Procedure 2000-37.
    Type: Application
    Filed: January 12, 2004
    Publication date: February 24, 2005
    Inventors: Andrew Gelson, Edwin Rivera, Edward Glazer, David Marcus
  • Publication number: 20040146529
    Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
    Type: Application
    Filed: November 17, 2003
    Publication date: July 29, 2004
    Applicant: Chiron Corporation
    Inventors: Mark Selby, Edward Glazer, Michael Houghton
  • Patent number: 6740323
    Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: May 25, 2004
    Assignee: Chiron Corporation
    Inventors: Mark Selby, Edward Glazer, Michael Houghton
  • Patent number: 6699862
    Abstract: Novel indolyl-2-phenyl bisamidines are described which are DNA methyltransferase inhibiting agents, and pharmaceutical compositions containing them are used as antiproliferative agents for treating a disease, especially a neoplastic disease, characterized by abnormally rapid proliferation of tissue involved in said disease; said indolyl-2-phenyl bisamidines comprising a and a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen or (C1-C3)alkyl; R3, R4, R5, R8, R9, and R10 are hydrogen or (C1-C3)alkyl, or R3 and R4 may be taken together, or R8 and R9 may be taken together with the nitrogen atoms to which they are attached, to form an imidazolinyl group; R14 is —H; —NHC(═O)(CH2)mR20; —(CH2)mR20; —CH(CH3)R20; —(CH2)m(C6H3)—R17; —(CH2)m(C6H3)—R20; —(CH2)m(heterocyclyl)—R17; —(CH2)m(heterocyclyl)—R20; —CH2CH═CHR20; —(CH2)mC(═O)NH—CHR20R21; or —(CH2)mC(═O)NH—CH2&m
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: March 2, 2004
    Assignee: Pfizer Inc.
    Inventors: Steven W. Goldstein, Banauara L. Mylari, Jose R. Perez, Edward A. Glazer
  • Publication number: 20040001854
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Application
    Filed: February 18, 2003
    Publication date: January 1, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Patent number: 6521423
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: February 18, 2003
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Patent number: 6329412
    Abstract: Known bisamidine compounds are newly discovered to possess DNA methyltransferase inhibiting properties, making them useful for preparing pharmaceutical compositions useful as antiproliferative agents for treating a neoplastic or a non-neoplastic disease characterized by abnormally rapid proliferation of tissue involved in said disease; wherein said bisamidines comprise a compound of Formula (5.0.0): and a pharmaceutically acceptable salt thereof, wherein: —X is —C(R34)—; or —N—; —R23, R24, R28 and R29 are each independently —H; or —CH2— where R23 and R24 and R28 and R29 are taken together with the nitrogen atoms to which they are attached, to form an imidazolinyl group; and —R34 is —H; or —CH3. A preferred species of Formula (5.0.0) is the following: 2-(4-Carbamimidoyl-phenyl)-1H-indole-6-carboxamidine.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: December 11, 2001
    Assignee: Pfizer Inc
    Inventors: Steven W. Goldstein, Banauara L. Mylari, Jose R. Perez, Edward A. Glazer
  • Patent number: 5552387
    Abstract: An antibiotic of the formula ##STR1## wherein R is hydrogen or a pharmaceutically acceptable cation and Me is methyl.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: September 3, 1996
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4920224
    Abstract: Variously substituted trans-3-[3-(3-hydroxypiperid-2-yl)-2-oxopropyl]quinazolin-4(3H)-ones, a method of controlling or preventing coccidiosis in poultry therewith, intermediates therefor, and a process for the preparation of certain intermediates therefor.
    Type: Grant
    Filed: March 13, 1989
    Date of Patent: April 24, 1990
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4849518
    Abstract: Variously substituted trans-3-[3-(3-hydroxypiperid-2-yl)-2-oxopropyl]quinazoline-4(3H)-ones, a method of controlling or preventing coccidiosis in poultry therewith, intermediates therefor, and a process for the preparation of certain intermediates thereof.
    Type: Grant
    Filed: March 24, 1988
    Date of Patent: July 18, 1989
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4797486
    Abstract: Certain trans-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]thieno[3,2-d]pyrimidin-4(3H )-one and furo[3,2-d]pyrimidin-4(3H)-one derivatives, a method of using same as anticoccidial agents, intermediates therefor, and a process for certain intermediates therefor.
    Type: Grant
    Filed: October 14, 1987
    Date of Patent: January 10, 1989
    Assignee: Pfizer Inc.
    Inventors: Edward A. Glazer, James W. McFarland
  • Patent number: 4762838
    Abstract: Variously substituted trans-3-[3-(3-hydroxypiperid-2-yl)-2-oxopropyl]quinazolin-4-(3H)-ones, a method of controlling or preventing coccidiosis in poultry therewith, intermediates therefor, and a process for the preparation of certain intermediates therefor.
    Type: Grant
    Filed: June 22, 1987
    Date of Patent: August 9, 1988
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4732907
    Abstract: Diamidines of the formula ##STR1## wherein X is a propylene, isobutylene, guanidine, pyrrole, tetrazole, imidazole or substituted imidazole group; and 2-[4-(2-imidazolinyl)phenyl]-6-(2-imidazolinyl)indole, are useful in the treatment of certain protozoal infections in mammals, particularly in cattle.
    Type: Grant
    Filed: July 25, 1986
    Date of Patent: March 22, 1988
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4725599
    Abstract: Certain trans-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]thieno[3,2-d]pyrimidin-4(3H )-one and furo[3,2-d]pyrimidin-4(3H)-one derivatives, a method of using same as anticoccidial agents, intermediates therefor, and a process for certain intermediates therefor.
    Type: Grant
    Filed: September 8, 1986
    Date of Patent: February 16, 1988
    Assignee: Pfizer Inc.
    Inventors: Edward A. Glazer, James W. McFarland
  • Patent number: 4624958
    Abstract: Diamidines of the formula ##STR1## wherein X is a propylene, isobutylene, guanidine, pyrrole, tetrazole, imidazole or substituted imidazole group; and 2-[4-(2-imidazolinyl)phenyl]-6-(2-imidazolinyl)indole, are useful in the treatment of certain protozoal infections in mammals, particularly in cattle.
    Type: Grant
    Filed: August 28, 1985
    Date of Patent: November 25, 1986
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 4546113
    Abstract: Diamidines of the formula ##STR1## wherein X is a propylene, isobutylene, guanidine, pyrrole, tetrazole, imidazole or substituted imidazole group; and 2-[4-(2-imidazolinyl)phenyl]-6-(2-imidazolinyl)indole, are useful in the treatment of certain protozoal infections in mammals, particularly in cattle.
    Type: Grant
    Filed: April 14, 1983
    Date of Patent: October 8, 1985
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer